Clostridium difficile: Improving the prevention paradigm in healthcare settings

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 9, 2014, Pages 1087-1102

  Vassallo, Angela ^a   Tran, Mai Chi N ^a   Goldstein, Ellie J C ^a,b,c  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c R M ALDEN RESEARCH LABORATORY   (United States)

Author keywords

antibiotic resistance; antibiotic stewardship; C. difficile bundle; Clostridium difficile; Clostridium difficile infection; contact isolation; contact precautions; disinfection; fecal microbiome; hand hygiene; hydrogen peroxide vapor infection prevention; probiotics; UV light

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DOXYCYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; TIGECYCLINE;

AGE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CHEMOTHERAPY; CLEANING; CLOSTRIDIUM DIFFICILE INFECTION; DISINFECTION; DRUG SAFETY; FECES MICROFLORA; HAND WASHING; HEALTH CARE FACILITY; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; IRRITABLE COLON; MICROBIOME; OBESITY; PATIENT CARE; REVIEW; RISK FACTOR; ULTRAVIOLET RADIATION; VACCINATION; COMPLICATION; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GROWTH, DEVELOPMENT AND AGING; INFECTION CONTROL; MICROBIOLOGY; MICROFLORA; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; TRANSMISSION;

AGE FACTORS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; INFECTION CONTROL; MICROBIOTA; RISK FACTORS;

EID: 84905868831     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.942284     Document Type: Review

References (188)

1. CDC. Available from: www.cdc.gov/HAI/organisms/cdiff/Cdiff/infect.htm [Last accessed 19 January 2014]
2. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe. Bacillus difficilis. Am J Dis Child 1935;49:390-402
3. Bartlett JG, Chang TW, Gurwith M, Gorbach SL. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978;298:531-4
4. Young VB, Hanna PC. Overlapping roles for toxins in C. difficile infection. J Infect Dis 2014;209:9-11
5. CDC. Available from: www.cdc.gov/VitalSigns/Hai/StoppingCdifficile/
6. Lucado J, Gould C, Elixhauser A. Clostridium difficile Infections (CDI) in hospital stays, 2009. HCUP Statistical Brief #124. Agency for Healthcare Research and Quality. 2012. Available from: www.hcupus. ahrq.gov/reports/ statbriefs/sb124.pdf [Last accessed 24 January 2014]
7. Tyler JA, Fox JP, Desai MM, et al. Outcomes and costs associated with robotic colectomy in the minimally invasive era. Dis Colon Rectum 2013;56(4):458-66
8. Jury LA, Sitzlar B, Kundrapu S, et al. Outpatient healthcare settings and transmission of Clostridium difficile. PLoS One 2013;8(7):e70175
9. Goldstein EJ. Anaerobic Bacteremia. Clin Infect Dis 1996;23(Suppl 1):S97-101
10. CDC. Available from: www.cdc.gov
11. McDonald LC, Kilgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353(23):2433-41
12. CDC. Available from: www.cdc.gov/NCIDOD/DHQP/pdf/guidelines/ Isolation2007.pdf
13. Gerding DN, Muto CA, Owens RC. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S43-9
14. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype Clin Infect Dis 2008;47:1162-70
15. Debast SB, van Leengoed LA, Goorhuis A, et al. Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environ Microbiol 2009;11:505-11
16. Bouttier S, Barc MC, Felix B, et al. Clostridium difficile in ground meat, France. Emerg Infect Dis 2010;16(4):733-5
17. Songer JG, Trinh HT, Killgore GE, et al. Clostridium difficile in retail meat products. Emerg Infect Dis 2009;15(5):819-21
18. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55
19. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40(1): 1-15
20. Specter M. Germs are us. The New Yorker. 2012. Available from: www.newyorker.com/reporting/2012/10/22/121022fa/fact/specter?currentPage=all
21. Rousseau C, Poilane I, De Pontual L, et al. Clostridium difficile carriage in healthy infants in the community: A potential reservoir for pathogenic strains. Clin Infect Dis 2012;55(9):1209-15
22. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota as revealed by deep 16S r RNA sequencing. PLoS Biol 2008;6(11):e280
23. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197(3):435-8
24. Pathak R, Enuh HA, Patel A, Wickremesinghe P. Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Clin Exp Gastroenterol 2013;7:1-6
25. Goorhuis A, Debast SB, Dutilh JC, et al. Type-specific risk factors and outcome in an outbreak with 2 different CDI types simultaneously in 1 hospital. Clin Infect Dis 2011;53(9):860-9
26. Debast SB, Vaessen N, Choudry A, et al. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009;15:427-34
27. Vardakas KZ, Konstantelias AA, Loizidis G, et al. Risk factors for development of CDI infection due to BI/NAP1/027 strain: A meta-analysis. Int J Infect Dis 2012; 16(11):e768-73
28. Gui J, Mustachio LM, Su DM, Craig RW. Thymus size and age-related thymic involution: early programming, sexual dimorphism, progenitors and stoma. Aging Dis 2012;3(3):280-90
29. Leung J, Burke B, Ford D, et al. Possible association between obesity and Clostridium difficile infection. Emerg Infect Dis 2013; 19(11):1791-8
30. Cox LM, Blaser MJ. Pathways in microbe-induced obesity. Cell Metab 2013; 17(6):883-94
31. Bishara J, Farah R, Mograbi J, et al. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis 2013;57: 489-93
32. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345-51
33. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci USA 2012;109:594-9
34. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-44
35. Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol 2010;16:4892-904
36. Li E, Hamm CM, Gulati AS, et al. Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One 2012;7: e26284
37. Fainstein V, Bodney GP, Fekety R. Relapsing pseudomenbranous colitis associated with cancer chemotherapy. J Infect Dis 1981; 143(6):865
38. Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2010;8(10):1113-19
39. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994;38(3):409-14
40. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004;39(2):219-26
41. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis 1993; 16(Suppl 4):S214-18
42. Mai V, Braden CR, Heckendorf J, et al. Monitoring of stool microbiota in subjects with diarrhea indicates distortions in composition. J Clin Microbiol 2006;44(12): 4550-2
43. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in composition of fecal microbiota. J Clin Microbiol 2004; 42(3):1203-6
44. Durand T, Lalande V, Petit JC, et al. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol 2008;56(3):395-402
45. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-8
46. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346(5):334-9
47. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-34
48. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26(3): 273-80
49. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353(23):2442-9
50. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults: A prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95-100
51. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol 1991;12:345-8
52. Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 2000;31:717-22
53. Nelson DE, Auerbach SB, Baltch AL, et al. Epidemic Clostridium difficile-associated diarrhea: role of second-and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994;15:88-94
54. Pultz NJ, Donskey CJ. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 2005;49:3529-32
55. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: A meta-analysis. J Antimicrob Chemother 2013;68(9):1951-61
56. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366(9491):1079-84
57. S?es L, M?lbak K, Str?baek S, et al. The emergence of Clostridium difficile ribotype 027 in Denmark-A possible link with the increased consumption of fluoroquinolones and cephalosporins? Euro Surveill 2009;14:15
58. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353(23):2433-41
59. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166(22): 2518-24
60. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974;81(4):429-33
61. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341(22):1645-51
62. Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120(4):272-7
63. Sambol SP, Merrigan MM, Tang JK, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002;186:1781-9
64. Larson HE, Borriello SP. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob Agents Chemother 1990;34:1348-53
65. Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272-7
66. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128(12 Pt 1):989-95
67. Pe?pin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004;171(5):466-72
68. Pe?pin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41(9):1254-60
69. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9(6):730-3
70. Bradford PA, Weaver-Sands T, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41(Suppl 5):S315-32
71. Noskin GA. Tigecycline: A new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14
72. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-44
73. Edlund C, Nord CE. In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000;6: 158-63
74. Nore?n T, Alriksson I, A ? kerlund T, et al. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infec 2010;16:1104-10
75. Freeman J, Wilcox MH. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2001;47: 244-6
76. Bourgault AM, Lamothe F, Loo VG, Poirier L; CDAD-CSI Study Group. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 2006;50: 3473-5
77. Garneau JR, Valiquette L, Fortier LC. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014;14(1):29
78. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006;58(5):1062-5
79. Jump RL, Li Y, Pultz MJ, et al. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 2011;55(2):546-9
80. Freeman J, Baines SD, Wilcox MH. Comparison of the efficacy of ramoplanin vs vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005;56:717-25
81. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48(12):1732-5
82. Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med 1997;157:1421-8
83. Robbins M, Marais R, Felmingham D, Ridgway GL. The in-vitro activity of doxycycline and minocycline against anaerobic bacteria. J Antimicrob Chemother 1987;20:379-82
84. Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of community-acquired Clostridium difficile associated diarrhea. J Infect Dis 1994;169:127-33
85. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infectioñ Clin Infect Dis 2012;55(5): 615-20
86. Baxter R, Ray G, Fireman B. Case-Control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:44-50
87. Piacenti FJ, Leuthner KD. Antimicrobial stewardship and clostridium difficile-associated diarrhea. J Pharm Pract 2013;26(5):506-13
88. Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005; CD003543
89. Valiquette L, Cossette B, Garant MP, et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(Suppl 2):S112-21
90. Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272-7
91. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128(12 pt 1):989-95
92. Clindamycin formulary restriction lowers costs, antimicrobial resistance. Am J Health Syst Pharm 1998;55(15):1552
93. Dancer SJ, Kirkpatrick P, Corcoran DS, et al. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum beta-lactamase-producing coliforms and methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2013;41(2):137-42
94. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38(5): 640-5
95. Aldeyab MA, Kearney MP, Scott MG, et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012; 67(12):2988-96
96. Carling P, Fung T, Killion A, et al. Favorable impact of multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003;24(9):699-706
97. Dancer SJ, Kirkpatrick P, Corcoran DS, et al. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum b-lactamase-producing coliforms and methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2013;41(2):137-42
98. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: A controlled interrupted time series. J Antimicrob Chemother 2007;59(5):990-5
99. Zilberberg MD, Shorr AF. Preventing Clostridium difficile infection in the intensive care unit. Crit Care Clin 2013; 29(1):11-18
100. Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology 1982; 83(2):465-9
101. Kaur S, Vaishnavi C, Prasad KK, et al. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol 2007;51(12):1209-14
102. Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis 1985;151:355-61
103. Tasteyre A, Karjalainen T, Avesani V, et al. Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups. J Clin Microbiol 2000;38:3179-86
104. Seddon SV, Hemingway I, Borriello SP. Hydrolytic enzyme production by Clostridium difficile and its relationship to toxin production and virulence in the hamster model. J Med Microbiol 1990;31: 169-74
105. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: A prospective randomised double blind study. Gut 1996;39(1):54-9
106. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2001;15(3):511-21
107. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra-and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30(5):1118-22
108. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors inhibitors effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000; 14(Suppl 1):74-81
109. Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 2000; 22(2):357-72
110. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am J Gastroenterol 2012;107(7):1001-10
111. Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: A contemporary systematic review and meta-analysis. PLoS ONE 2012;7(12): e50836
112. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107(7):1011-19
113. Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol 2012;107(7):1020-1
114. Freedberg DE, Abrams JA. Does confounding explain the association between PPIs and Clostridium difficile-related diarrheä Am J Gastroenterol 2013;108(2): 278-9
115. Chandra S, Agarwal D, Surana A. Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation Am J Gastroenterol 2013; 108(2):277-8
116. King RN, Lager SL. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy. Pharmacotherapy 2011;31(7):642-8
117. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent clostridium difficile infection among inpatients. Am J Gastroenterol 2013. [Epub ahead of print]
118. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs. Available from: www.fda.gov/drugs/drugsafety/ucm290510.htm#sa
119. Moayyedi P, Leontiadis GI. Risks of proton pump inhibitor therapy. Nat Rev Gastroenterol Hepatol 2012;9(3):132-9
120. Cadle RM, Mansouri MD, Logan N, et al. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007;64(22): 2359-63
121. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170(9):772-8
122. Barletta JF, El-Ibiary SY, Davis LE, et al. Proton pump inhibitors and the risk for hospital-acquired clostridium difficile infection. Mayo Clin Proc 2013;88(10): 1085-90
123. Sullivan A, Nord CE. Probiotics in human infections. J Antimicrob Chemother 2002; 50(5):625-7
124. Gueimonde M, Salminen S. New methods for selecting and evaluating probiotics. Dig Liver Dis 2006;38(Suppl 2):S242-7
125. Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 2009;9:237-44
126. Maziade PJ, Andriessen JA, Pereira P, et al. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013;29(10):1341-7
127. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: A systematic review and meta-analysis. Ann Intern Med 2012;157:878-88
128. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: A systematic review and metaanalysis. JAMA 2012; 307(18):1959-69
129. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013;5:CD006095
130. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335(7610):80
131. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol 2011;4(3):185-97
132. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 2013;7(2):e56-67
133. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636-41
134. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004;7(1):59-62
135. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013. [Epub ahead of print]
136. Cohen SH, Gerding DN, Johnson S, et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55
137. Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 2011(200):1-645
138. Theodorakopoulou M, Perros E, Giamarellos-Bourboulis EJ, Dimopoulos G. Controversies in the management of the critically ill: the role of probiotics. Int J Antimicrob Agents 2013;42 Suppl:S41-4
139. Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012;16(11): e786-92
140. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62
141. Pothoulakis C. Pathogenesis of Clostridium difficile-associated diarrhoea. Eur J Gastroenterol Hepatol 1996;8:1041-7
142. Riegler M, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995;95: 2004-11
143. Kyne L, Warner M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum level of IgG antibody against toxin A. N Engl J Med 2000; 342(6):390-7
144. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001; 357(9251):189-93
145. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145(10):758-64
146. Yang XQ, Zhao YG, Chen XQ, et al. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model. BMC Gastroenterol 2013;13:117
147. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69(2):988-95
148. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003;71(3):1608-10
149. Study of different formulations of a clostridium difficile toxoid vaccine given at three different schedules in adults. Available from: www.clinicaltrials.gov/ct2/results? term=NCT01230957&Search=Search
150. Study of a clostridium difficile toxoid vaccine (ACAM-CDIFFTM) in subjects with clostridium difficile infection. Available from: www.clinicaltrials.gov/ct2/results? term=NCT00772343&Search=Search
151. Cdiffense. Available from: www.cdiffense. Org
152. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004; 109(21 Suppl 1):II-42-8
153. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21
154. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118
155. Motzkus-Feagans CA, Pakyz A, Polk R, et al. Statin use and the risk of CDI in academic medical centres. Gut 2012;61(11): 1538-42
156. Nseir W, Bishara J, Mograbi J, et al. Do statins protect against the development of CDI-associated diarrhoeä J Antimicrob Chemother 2013;68(8):1889-93
157. Park SW, Choi AR, Lee HJ, et al. The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 2013; 38(6):619-27
158. Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated CDI infection: no role for proton pump inhibitor. Am J Med 2011;124(3):276.e1-7
159. Dobesh PP, Klepser DG, McGuire TR, et al. Statins associated with a reduction in mortality in patients with sepsis. Pharmacotherapy 2009;29:621-30
160. McGuire T, Dobesh P, Klepser D, et al. Clinically important interaction between statin drugs and CDI toxiñ Med Hypotheses 2009;73(6):1045-7
161. Sydnor ER, Perl T. Hospital epidemiology and infection control in acute care settings. Clin Microbiol Rev 2011;24(1):141-73
162. CDC. Type and duration of precautions recommended for selected infections and conditions, Appendix A. Available from: www.cdc.gov/hicpac/2007ip/2007ip/ appenda.html
163. Dubberke ER, Gerding DN. Rationale for hand hygiene recommendations after caring for a patient with Clostridium difficile Infection. a compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Fall 2011 Update
164. Landelle C, Verachten M, Legrand P, et al. Contamination of healthcare workers' hands with Clostridium difficile spores after caring for patients with C. difficile Infection. Infect Control Hosp Epidemiol 2014;35(1):10-15
165. Dumford DM, Nerandzic MM, Eckstein BC, Donskey CJ. What is on that keyboard? Detecting hidden environmental reservoirs of Clostidium difficile during an outbreak associated with North American pulsed-field gel electrophoresis type I strains. Am J Infect Control 2009;37(1):15-19
166. Available from: www.epa.gov/oppad001/chemregindex.htm
167. Available from: www.bioquell.com/products/
168. Passaretti CL, Otter J, Reich NG, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug resistant organisms. Clin Infect Dis 2013;56(1):27-35
169. Available from: http://singularityhub.com/2013/01/13/uv-light-emitting- robotdisinfects-hospital-rooms-in-minutes/
170. Available from: www.timesunion.com/local/article/With-a-zap-germs-meet- their-match-3507541.php
171. Stibich MS, Stachowiak J, Tanner B, et al. Evaluation of pulsed xenon ultraviolet room disinfection device for impact on hospital operations and microbial reduction. Infect Control Hosp Epidemiol 2011;32(3):286-8
172. Levin J, Riley LS, Parrish C, et al. The effect of portable pulsed xenon ultraviolet light after terminal cleaning on hospital-associated Clostridium difficile infection in a community hospital. Am J Infect Control 2013;41:746-8
173. Fornwalt L, Riddell B. Implementation of innovative pulsed xenon ultraviolet (PXUV) environmental cleaning in an acute care hospital. Risk Manag Healthc Policy 2014;7:25-8
174. Barbut F, Yezli S, Mimoun M, et al. Reducing the Spread of Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus on a burns unit through the intervention of an infection control bundle. Burns 2012.39(3):395-403. Available from: http//dx.doi.org/10.1016/j. burns.2012.07.007
175. APIC, Guide to the Elimination of Clostridium difficile in Healthcare Settings. 2008. Available from: www.apic.org/Resource/EliminationGuideForm/ 5de5d1c1-316a-4b5e-b9b4-c3fbeac1b53e/File/APIC-Cdiff-Elimination-Guide.pdf
176. Feazel LM, Malhotra A, Perecevich EN, et al. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: A systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1748-54
177. Available from: www.isixsigma.com/implementation/change- managementimplementation/preventing-conflictsthrough-stakeholder-management/
178. Miller BA. ICHE. 2011;32(4):387-90
179. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Infect Dis 2012; 55(Suppl 2):S132-42
180. Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent Clostridium. difficile infections in acute care hospitals: 2014 Update. Infect Control Hosp Epidemiol 2014;35(6):628-45
181. CDC. Available from: www.cdc.gov/HAI/organisms/cdiff/Cdiff/clinicians. html
182. Pakyz AL, Jawahar R, Wang Q, Harpe SE. Medication risk factors associated with healthcare-associated Clostridium difficile infection: A multilevel model case-control study among 64 US academic medical centres. J Antimicrob Chemother 2014; 69(4):1127-31
183. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69(4):881-91
184. van der Kooi TI, Koningstein M, Lindemans A, et al. Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype. J Med Microbiol 2008; 57(Pt 6):709-16
185. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29(1):44-50
186. Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011; 66(9):2168-74
187. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-19
188. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infection. Am J Gastroenterol 2013;108:478-98